Raludotatug deruxtecan shows 50.5% response rate in ovarian cancer trial
PositiveFinancial Markets

The recent clinical trial of raludotatug deruxtecan has shown a promising 50.5% response rate in patients with ovarian cancer. This is significant as it highlights a potential new treatment option for a disease that often has limited effective therapies. The results could pave the way for further research and development, offering hope to many who are battling this challenging condition.
— Curated by the World Pulse Now AI Editorial System